Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
47.55
+0.14 (0.30%)
At close: Mar 3, 2025, 4:00 PM
47.90
+0.35 (0.74%)
After-hours: Mar 3, 2025, 6:09 PM EST

Company Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.

It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer.

The company’s pipeline focus on advancing screening and diagnostic products including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring.

The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University.

Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation
Exact Sciences logo
Country United States
Founded 1995
Industry Diagnostics & Research
Sector Healthcare
Employees 7,000
CEO Kevin Conroy

Contact Details

Address:
5505 Endeavor Lane
Madison, Wisconsin 53719
United States
Phone 608 284 5700
Website exactsciences.com

Stock Details

Ticker Symbol EXAS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001124140
CUSIP Number 30063P105
ISIN Number US30063P1057
Employer ID 20-4782291
SIC Code 8071

Key Executives

Name Position
Kevin T. Conroy J.D. Chairman of the Board and Chief Executive Officer
Jake Orville MBA Executive Vice President and GM of Screening
Brian Baranick Executive Vice President and General Manager of Precision Oncology
Aaron Bloomer Chief Financial Officer
Dr. Jorge A. Garces Ph.D. Chief Science Officer
Nassar Nizami Chief Information Officer
James Herriott Senior Vice President, General Counsel and Secretary
Sarah Condella Executive Vice President of Human Resources
Graham P. Lidgard Ph.D. Emeritus Chief Science Officer
Ana Hooker Chief Laboratory Officer

Latest SEC Filings

Date Type Title
Feb 19, 2025 10-K Annual Report
Feb 19, 2025 8-K Current Report
Feb 10, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Jan 6, 2025 8-K Current Report
Nov 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 5, 2024 10-Q Quarterly Report
Nov 5, 2024 8-K Current Report
Oct 8, 2024 144 Filing